# CorMedix Inc.: financial statements, quarterly

CRMD · Nasdaq · CIK 1410098 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crmd.md) · [Financials](/companies/crmd/financials.md) · [Filings](/companies/crmd/filings.md) · [Insiders](/companies/crmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [0.8](/filings/0001213900-25-072843.md) | [11.5](/filings/0001213900-25-108777.md) | [31.2 d](/filings/0001213900-26-023889.md) | [39.1](/filings/0001410098-26-000021.md) | [39.7](/filings/0001410098-26-000056.md) | [104](/filings/0001213900-25-108777.md) | [129 d](/filings/0001213900-26-023889.md) | [127](/filings/0001410098-26-000021.md) | [102](/filings/0001410098-26-000056.md) |
| Cost of revenue | $m | not reported | not reported | [0.8](/filings/0001213900-25-039908.md) | [0.5](/filings/0001213900-25-072843.md) | [0.6](/filings/0001213900-25-108777.md) | [1.1 d](/filings/0001213900-26-023889.md) | [1.5](/filings/0001410098-26-000021.md) | [1.9](/filings/0001213900-25-072843.md) | [7.6](/filings/0001213900-25-108777.md) | [11.2 d](/filings/0001213900-26-023889.md) | [12.0](/filings/0001410098-26-000021.md) | not reported |
| Gross profit | $m | not reported | not reported | [(0.8)](/filings/0001213900-25-039908.md) | [0.3](/filings/0001213900-25-072843.md) | [10.8](/filings/0001213900-25-108777.md) | [30.0 d](/filings/0001213900-26-023889.md) | [37.5](/filings/0001410098-26-000021.md) | [37.9](/filings/0001410098-26-000056.md) | [93.1](/filings/0001213900-25-108777.md) | [107 d](/filings/0001213900-26-023889.md) | [105](/filings/0001410098-26-000021.md) | [77.1](/filings/0001410098-26-000056.md) |
| Research and development | $m | [2.7](/filings/0001213900-24-091961.md) | [2.3 d](/filings/0001013762-25-001852.md) | [0.8](/filings/0001213900-25-039908.md) | [0.7](/filings/0001213900-25-072843.md) | [0.7](/filings/0001213900-25-108777.md) | [1.7 d](/filings/0001213900-26-023889.md) | [3.2](/filings/0001410098-26-000021.md) | [2.4](/filings/0001410098-26-000056.md) | [5.1](/filings/0001213900-25-108777.md) | [8.6 d](/filings/0001213900-26-023889.md) | [7.2](/filings/0001410098-26-000021.md) | [6.7](/filings/0001410098-26-000056.md) |
| Selling, general and administrative | $m | [7.8](/filings/0001213900-23-086981.md) | [13.4 d](/filings/0001213900-24-021585.md) | [15.0](/filings/0001213900-24-041031.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(10.5)](/filings/0001213900-24-091961.md) | [(15.7) d](/filings/0001013762-25-001852.md) | [(16.7)](/filings/0001213900-25-039908.md) | [(15.3)](/filings/0001213900-25-072843.md) | [(3.3)](/filings/0001213900-25-108777.md) | [12.9 d](/filings/0001213900-26-023889.md) | [20.1](/filings/0001410098-26-000021.md) | [19.5](/filings/0001410098-26-000056.md) | [51.3](/filings/0001213900-25-108777.md) | [59.1 d](/filings/0001213900-26-023889.md) | [63.7](/filings/0001410098-26-000021.md) | [42.9](/filings/0001410098-26-000056.md) |
| Interest expense | $m | [0.0](/filings/0001213900-23-086981.md) | [0.0 d](/filings/0001213900-24-021585.md) | [0.0](/filings/0001213900-24-041031.md) | [0.0](/filings/0001213900-24-068600.md) | [0.0](/filings/0001213900-25-108777.md) | [0.0 d](/filings/0001213900-26-023889.md) | [0.0](/filings/0001213900-25-039908.md) | [0.0](/filings/0001213900-25-072843.md) | [0.9](/filings/0001213900-25-108777.md) | [1.8 d](/filings/0001213900-26-023889.md) | not reported | not reported |
| Income tax | $m | not reported | not reported | [(1.4)](/filings/0001213900-25-039908.md) | [0.0 d](/filings/0001213900-25-072843.md) | [0.0 d](/filings/0001213900-25-108777.md) | [(0.0) d](/filings/0001213900-26-023889.md) | [0.0](/filings/0001410098-26-000021.md) | [0.5](/filings/0001410098-26-000056.md) | [(56.0)](/filings/0001213900-25-108777.md) | [42.4 d](/filings/0001213900-26-023889.md) | [17.0](/filings/0001410098-26-000021.md) | [12.7](/filings/0001410098-26-000056.md) |
| Net income | $m | [(9.7)](/filings/0001213900-24-091961.md) | [(14.8) d](/filings/0001013762-25-001852.md) | [(14.5)](/filings/0001213900-25-039908.md) | [(14.2)](/filings/0001213900-25-072843.md) | [(2.8)](/filings/0001213900-25-108777.md) | [13.5 d](/filings/0001213900-26-023889.md) | [20.6](/filings/0001410098-26-000021.md) | [19.8](/filings/0001410098-26-000056.md) | [109](/filings/0001213900-25-108777.md) | [14.0 d](/filings/0001213900-26-023889.md) | [38.6](/filings/0001410098-26-000021.md) | [26.0](/filings/0001410098-26-000056.md) |
| Diluted EPS | $ per share | [(0.17)](/filings/0001213900-24-091961.md) | not reported | [(0.25)](/filings/0001213900-25-039908.md) | [(0.25)](/filings/0001213900-25-072843.md) | [(0.05)](/filings/0001213900-25-108777.md) | not reported | [0.30](/filings/0001410098-26-000021.md) | [0.28](/filings/0001410098-26-000056.md) | [1.26](/filings/0001213900-25-108777.md) | not reported | [0.43](/filings/0001410098-26-000021.md) | [0.29](/filings/0001410098-26-000056.md) |
| Basic EPS | $ per share | [(0.17)](/filings/0001213900-24-091961.md) | not reported | [(0.25)](/filings/0001213900-25-039908.md) | [(0.25)](/filings/0001213900-25-072843.md) | [(0.05)](/filings/0001213900-25-108777.md) | not reported | [0.32](/filings/0001410098-26-000021.md) | [0.29](/filings/0001410098-26-000056.md) | [1.42](/filings/0001213900-25-108777.md) | not reported | [0.48](/filings/0001410098-26-000021.md) | [0.33](/filings/0001410098-26-000056.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [53.3](/filings/0001213900-24-091961.md) | [43.6](/filings/0001013762-25-001852.md) | [35.2](/filings/0001213900-25-039908.md) | [28.5](/filings/0001213900-25-072843.md) | [35.3](/filings/0001213900-25-108777.md) | [40.7](/filings/0001213900-26-023889.md) | [66.3](/filings/0001410098-26-000021.md) | [159](/filings/0001410098-26-000056.md) | [48.5](/filings/0001213900-25-108777.md) | [145](/filings/0001410098-26-000056.md) | [178](/filings/0001410098-26-000021.md) | [257](/filings/0001410098-26-000056.md) |
| Current assets | $m | [89.1](/filings/0001213900-23-086981.md) | [79.5](/filings/0001013762-25-001852.md) | [63.4](/filings/0001213900-24-041031.md) | [53.2](/filings/0001213900-24-068600.md) | [73.2](/filings/0001213900-24-091961.md) | [115](/filings/0001213900-26-023889.md) | [145](/filings/0001213900-25-039908.md) | [248](/filings/0001213900-25-072843.md) | [260](/filings/0001213900-25-108777.md) | [367](/filings/0001410098-26-000056.md) | [383](/filings/0001410098-26-000021.md) | [481](/filings/0001410098-26-000056.md) |
| Total assets | $m | [91.4](/filings/0001213900-23-086981.md) | [82.1](/filings/0001013762-25-001852.md) | [68.0](/filings/0001213900-24-041031.md) | [57.7](/filings/0001213900-24-068600.md) | [77.6](/filings/0001213900-24-091961.md) | [119](/filings/0001213900-26-023889.md) | [150](/filings/0001213900-25-039908.md) | [253](/filings/0001213900-25-072843.md) | [751](/filings/0001213900-25-108777.md) | [826](/filings/0001410098-26-000056.md) | [816](/filings/0001410098-26-000021.md) | [904](/filings/0001410098-26-000056.md) |
| Current liabilities | $m | [7.7](/filings/0001213900-23-086981.md) | [11.4](/filings/0001013762-25-001852.md) | [9.5](/filings/0001213900-24-041031.md) | [11.1](/filings/0001213900-24-068600.md) | [18.5](/filings/0001213900-24-091961.md) | [33.8](/filings/0001213900-26-023889.md) | [34.4](/filings/0001213900-25-039908.md) | [31.7](/filings/0001213900-25-072843.md) | [134](/filings/0001213900-25-108777.md) | [174](/filings/0001410098-26-000056.md) | [129](/filings/0001410098-26-000021.md) | [187](/filings/0001410098-26-000056.md) |
| Total liabilities | $m | [8.2](/filings/0001213900-23-086981.md) | [11.9](/filings/0001013762-25-001852.md) | [10.0](/filings/0001213900-24-041031.md) | [11.5](/filings/0001213900-24-068600.md) | [18.9](/filings/0001213900-24-091961.md) | [34.2](/filings/0001213900-26-023889.md) | [34.7](/filings/0001213900-25-039908.md) | [32.0](/filings/0001213900-25-072843.md) | [377](/filings/0001213900-25-108777.md) | [421](/filings/0001410098-26-000056.md) | [379](/filings/0001410098-26-000021.md) | [443](/filings/0001410098-26-000056.md) |
| Shareholders' equity | $m | [83.2](/filings/0001213900-24-091961.md) | [70.1](/filings/0001213900-26-023889.md) | [58.0](/filings/0001213900-25-072843.md) | [46.2](/filings/0001213900-25-108777.md) | [58.7](/filings/0001213900-25-108777.md) | [84.7](/filings/0001410098-26-000056.md) | [115](/filings/0001410098-26-000056.md) | [221](/filings/0001410098-26-000056.md) | [374](/filings/0001213900-25-108777.md) | [405](/filings/0001410098-26-000056.md) | [437](/filings/0001410098-26-000056.md) | [461](/filings/0001410098-26-000056.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.7) d](/filings/0001213900-24-091961.md) | [(10.7) d](/filings/0001013762-25-001852.md) | [(17.3)](/filings/0001213900-25-039908.md) | [(14.0) d](/filings/0001213900-25-072843.md) | [(13.6) d](/filings/0001213900-25-108777.md) | [(5.6) d](/filings/0001213900-26-023889.md) | [19.7](/filings/0001410098-26-000021.md) | [30.0 d](/filings/0001410098-26-000056.md) | [30.9 d](/filings/0001213900-25-108777.md) | [94.5 d](/filings/0001213900-26-023889.md) | [42.4](/filings/0001410098-26-000021.md) | [86.2 d](/filings/0001410098-26-000056.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001213900-24-091961.md) | [0.3 d](/filings/0001013762-25-001852.md) | [0.1](/filings/0001213900-25-039908.md) | [0.0 d](/filings/0001213900-25-072843.md) | [0.0 d](/filings/0001213900-25-108777.md) | [0.0 d](/filings/0001213900-26-023889.md) | [0.0](/filings/0001410098-26-000021.md) | [0.0 d](/filings/0001410098-26-000056.md) | [0.5 d](/filings/0001213900-25-108777.md) | [1.7 d](/filings/0001213900-26-023889.md) | [0.7](/filings/0001410098-26-000021.md) | [0.6 d](/filings/0001410098-26-000056.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001410098-26-000021.md) | [0.0 d](/filings/0001410098-26-000056.md) | not reported | not reported | [11.1](/filings/0001410098-26-000021.md) | [6.4 d](/filings/0001410098-26-000056.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [41.2](/filings/0001213900-23-086981.md) | [44.1](/filings/0001213900-24-041031.md) | [45.4](/filings/0001213900-24-068600.md) | [56.6](/filings/0001213900-24-091961.md) | [57.5](/filings/0001213900-25-039908.md) | [57.6](/filings/0001213900-25-072843.md) | [58.8](/filings/0001213900-25-108777.md) | [69.0](/filings/0001410098-26-000021.md) | [71.9](/filings/0001410098-26-000056.md) | [86.2](/filings/0001213900-25-108777.md) | [93.0](/filings/0001410098-26-000021.md) | [92.5](/filings/0001410098-26-000056.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 77,944,324 at 2026-08-10, from the cover of the [10-Q filed 2026-08-13](/filings/0001410098-26-000056.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.